Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Colorectal cancer AND SOCS1, O15524, 8651, ENSG00000185338, SOCS-1, SSI-1, SSI1, Cish1, JAB, CISH1, CIS1, TIP3 AND Treatment
16 results:

  • 1. Clinical and molecular assessment of an onco-immune signature with prognostic significance in patients with colorectal cancer.
    Ahluwalia P; Mondal AK; Ahluwalia M; Sahajpal NS; Jones K; Jilani Y; Gahlay GK; Barrett A; Kota V; Rojiani AM; Kolhe R
    Cancer Med; 2022 Mar; 11(6):1573-1586. PubMed ID: 35137551
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. 5-aminosalicylic acid inhibits the expression of oncomiRs and pro-inflammatory microRNAs: an in vitro study.
    Adamowicz M; Milkiewicz P; Kempinska-Podhorodecka A
    J Physiol Pharmacol; 2021 Aug; 72(4):. PubMed ID: 34987126
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. MiR-196: emerging of a new potential therapeutic target and biomarker in colorectal cancer.
    Pourdavoud P; Pakzad B; Mosallaei M; Saadatian Z; Esmaeilzadeh E; Alimolaie A; Shaygannejad A
    Mol Biol Rep; 2020 Dec; 47(12):9913-9920. PubMed ID: 33130965
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. socs1 Represses Fractionated Ionizing Radiation-Induced EMT Signaling Pathways through the Counter-Regulation of ROS-Scavenging and ROS-Generating Systems.
    Kim S; Kim SH; Lee CE
    Cell Physiol Biochem; 2020 Oct; 54(5):1026-1040. PubMed ID: 33048478
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Comparative Oncologic Outcomes of Upper Third Rectal cancers: A Meta-analysis.
    Clancy C; Flanagan M; Marinello F; O'Neill BD; McNamara D; Burke JP
    Clin Colorectal Cancer; 2019 Dec; 18(4):e361-e367. PubMed ID: 31445919
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Association of CHFR Promoter Methylation with treatment Outcomes of Irinotecan-Based Chemotherapy in Metastatic colorectal cancer.
    Cha Y; Kim SY; Yeo HY; Baek JY; Choi MK; Jung KH; Dong SM; Chang HJ
    Neoplasia; 2019 Jan; 21(1):146-155. PubMed ID: 30562637
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Prognostic Value of Methylator Phenotype in Stage III Colon cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy.
    Gallois C; Taieb J; Le Corre D; Le Malicot K; Tabernero J; Mulot C; Seitz JF; Aparicio T; Folprecht G; Lepage C; Mini E; Van Laethem JL; Emile JF; Laurent-Puig P;
    Clin Cancer Res; 2018 Oct; 24(19):4745-4753. PubMed ID: 29921730
    [No Abstract]    [Full Text] [Related]  

  • 8. The CpG island methylator phenotype is concordant between primary colorectal carcinoma and matched distant metastases.
    Cohen SA; Yu M; Baker K; Redman M; Wu C; Heinzerling TJ; Wirtz RM; Charalambous E; Pentheroudakis G; Kotoula V; Kalogeras KT; Fountzilas G; Grady WM
    Clin Epigenetics; 2017; 9():46. PubMed ID: 28469732
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Mechanism of suppressors of cytokine signaling 1 inhibition of epithelial-mesenchymal transition signaling through ROS regulation in colon cancer cells: suppression of Src leading to thioredoxin up-regulation.
    Jung SH; Kim SM; Lee CE
    Oncotarget; 2016 Sep; 7(38):62559-62571. PubMed ID: 27613835
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Promoter methylation and expression of socs-1 affect clinical outcome and epithelial-mesenchymal transition in colorectal cancer.
    Kang XC; Chen ML; Yang F; Gao BQ; Yang QH; Zheng WW; Hao S
    Biomed Pharmacother; 2016 May; 80():23-29. PubMed ID: 27133036
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. CpG island methylator phenotype is associated with response to adjuvant irinotecan-based therapy for stage III colon cancer.
    Shiovitz S; Bertagnolli MM; Renfro LA; Nam E; Foster NR; Dzieciatkowski S; Luo Y; Lao VV; Monnat RJ; Emond MJ; Maizels N; Niedzwiecki D; Goldberg RM; Saltz LB; Venook A; Warren RS; Grady WM;
    Gastroenterology; 2014 Sep; 147(3):637-45. PubMed ID: 24859205
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer.
    Han SW; Lee HJ; Bae JM; Cho NY; Lee KH; Kim TY; Oh DY; Im SA; Bang YJ; Jeong SY; Park KJ; Park JG; Kang GH; Kim TY
    Int J Cancer; 2013 May; 132(9):2209-16. PubMed ID: 23034738
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer.
    Jo P; Jung K; Grade M; Conradi LC; Wolff HA; Kitz J; Becker H; Rüschoff J; Hartmann A; Beissbarth T; Müller-Dornieden A; Ghadimi M; Schneider-Stock R; Gaedcke J
    Surgery; 2012 Apr; 151(4):564-70. PubMed ID: 22001634
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. 5-Fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer.
    Jover R; Nguyen TP; Pérez-Carbonell L; Zapater P; Payá A; Alenda C; Rojas E; Cubiella J; Balaguer F; Morillas JD; Clofent J; Bujanda L; Reñé JM; Bessa X; Xicola RM; Nicolás-Pérez D; Castells A; Andreu M; Llor X; Boland CR; Goel A
    Gastroenterology; 2011 Apr; 140(4):1174-81. PubMed ID: 21185836
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Aberrant DNA methylation in hereditary nonpolyposis colorectal cancer without mismatch repair deficiency.
    Goel A; Xicola RM; Nguyen TP; Doyle BJ; Sohn VR; Bandipalliam P; Rozek LS; Reyes J; Cordero C; Balaguer F; Castells A; Jover R; Andreu M; Syngal S; Boland CR; Llor X
    Gastroenterology; 2010 May; 138(5):1854-62. PubMed ID: 20102720
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma.
    Ogino S; Meyerhardt JA; Kawasaki T; Clark JW; Ryan DP; Kulke MH; Enzinger PC; Wolpin BM; Loda M; Fuchs CS
    Virchows Arch; 2007 May; 450(5):529-37. PubMed ID: 17372756
    [TBL] [Abstract] [Full Text] [Related]  

    of 1.